Targeting CREB Pathway Suppresses Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Small cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer with a poor prognosis.
• The roles of transcription factors NF-κB and CREB in SCLC pathogenesis are not well understood.
• NF-κB typically promotes tumor progression in many cancers, including non-small cell lung carcinoma (NSCLC).

Purpose of the Study:

• To investigate the roles of NF-κB and CREB transcription factors in SCLC development and progression.
• To explore the therapeutic potential of targeting the CREB pathway in SCLC.

Main Methods:

• Development of a lentiviral vector-mediated SCLC mouse model.
• Analysis of NF-κB and CREB activity in SCLC tumors (mouse and human).
• Inhibition of CREB activation using a dominant-negative PKA (dnPKA) and PKA inhibitor H89 in mouse models.

Main Results:

• NF-κB activity is dispensable and its suppression accelerates SCLC tumor development.
• SCLC tumors exhibit low NF-κB but high CREB activity.
• Blocking CREB activation (dnPKA) or inhibiting PKA (H89) completely abolished SCLC development and reduced tumor growth.

Conclusions:

• CREB transcription factor activity is essential for maintaining the neuroendocrine signature and proliferation of SCLC cells.
• Targeting the CREB pathway represents a promising therapeutic strategy for SCLC.
• This study highlights the critical role of CREB in SCLC and suggests new avenues for treatment development.